Aurora Cannabis stock analysis
Want to see TSE:ACB full AI Analyst Report?
Aurora Cannabis (ACB) Stock Price & Analysis
ACB Stock Chart & Stats
- Day’s Range
- CAD 6.11 - CAD 6.35
- 52-Week Range
- CAD 3.59 - CAD 8.75
- Previous Close
- CAD 6.31
- Volume
- N/A
- Average Volume (3M)
- 481.78K
- Market Cap
- CAD 414.85M
- Enterprise Value
- CAD 250.46M
- Total Cash (Recent Filing)
- CAD 83.62M
- Total Debt (Recent Filing)
- CAD 21.43M
- Price to Earnings (P/E)
- ―
- Beta
- 1.63
- Next Earnings
- Feb 10, 2027 (Est.)
- EPS Estimate
- -0.07
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
International Expansion
International medical revenue growth and a rising share of sales outside Canada indicate Aurora is building a broader regulated-market platform. Leadership in Germany, Poland, and Australia can support repeatable expansion as additional international markets develop.
Yield Improvement
Genetics and plant-science capabilities could raise output without a proportional increase in the cost base. If realized consistently, this productivity advantage can improve unit economics, support more competitive pricing, and strengthen margins as international volumes expand.
Balance Sheet Strength
Substantial liquidity combined with zero debt gives Aurora flexibility to fund operations, expand regulated-market capacity, and pursue acquisitions without immediate financing pressure. This balance-sheet strength also provides resilience while the company works through its transitionary period.
Bears Say
Revenue Contraction
The sharp TTM revenue decline and renewed net loss indicate that Aurora has not yet established stable, scalable demand across its business. Revenue contraction can dilute fixed-cost absorption and makes the durability of recent margin improvements less certain.
Negative Cash Generation
Ongoing negative operating and free cash flow means the business is still consuming cash despite improvement from earlier periods. If this pattern persists, it could reduce liquidity available for growth initiatives and increase dependence on the existing cash reserve.
Canadian Reimbursement Pressure
The reimbursement reduction directly pressures Canadian medical revenue and adjusted gross profit, creating a structural headwind rather than a temporary demand fluctuation. Lower reimbursement can also limit pricing power and make profitable domestic growth harder to sustain.
Aurora Cannabis News
ACB FAQ
What was Aurora Cannabis’s price range in the past 12 months?
What is Aurora Cannabis’s market cap?
When is Aurora Cannabis’s upcoming earnings report date?
How were Aurora Cannabis’s earnings last quarter?
Is Aurora Cannabis overvalued?
Does Aurora Cannabis pay dividends?
What is Aurora Cannabis’s EPS estimate?
How many shares outstanding does Aurora Cannabis have?
What happened to Aurora Cannabis’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Aurora Cannabis?
What is the TipRanks Smart Score and how is it calculated?
Aurora Cannabis Stock Smart Score
Company Description
Aurora Cannabis
Aurora Cannabis Inc. is a leading company in the global cannabis industry, focusing on the cultivation, production, and sale of various cannabis and cannabis-derived products across Canada and internationally. Beyond its core product offerings, the company engages in a broad spectrum of related activities, including the design and engineering of facilities, cannabis breeding programs, research and development, and both wholesale and retail distribution channels. For medical users, Aurora provides a diverse selection of products such as different strains of dried cannabis, cannabis oils, capsules, and topical kits. Their inventory also includes ancillary items like vaporizers, vaporizer accessories, herb mills (specifically for CanniMed products), grinders, and secure containers for vaporizers. The company is actively involved in developing advanced medical cannabis products, with ongoing work on oral, topical, edible, and inhalable formulations. Furthermore, Aurora manages CanvasRX, a network of centers dedicated to cannabis counseling and community outreach. Its service portfolio extends to providing patient support, specialized design and construction services, and comprehensive analytical testing for cannabis products. Aurora Cannabis Inc. manages an extensive collection of brands, including Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and WMMC. The company's main corporate office is located in Edmonton, Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Miguel Martin
- Employees
- 1,028
- Website
- www.auroramj.com
- Address
- 90B Street SW, Edmonton, AB, T6X 1V8, CA
Aurora Cannabis (ACB) Earnings & Revenues
ACB Company Deck
ACB Earnings Call
Earnings Call SentimentNeutral
The call presents a balanced picture: material short-term financial headwinds (notably a large year-over-year decline in adjusted EBITDA, lower adjusted net income, and negative free cash flow) driven largely by an external 30% reimbursement cut in Canadian medical. Offsetting these negatives are clear strategic strengths—17% international revenue growth to $43M, a 58% adjusted gross margin, strong cash position with no debt, an accretive EU GMP acquisition (Safari), genetics-driven production advantages (up to 40% yield improvement), and market leadership in several regulated international markets. Management frames FY2027 as a transitionary year with expected sequential improvement in Q2 and reiterated long-term targets (sustained double-digit growth and superior margins). Given the mix of significant near-term financial declines and pronounced strategic/operational positives, the overall tone is balanced.
View all TSE:ACB earnings summariesACB Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 10 | 5 | 7 |
| Technical Analysis | 4 | 5 | 1 |
| Moving Averages | 6 | 0 | 6 |











